Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4006
Source ID: NCT00191581
Associated Drug: Humalog Mix 50
Title: Local Registration Trial in China Humalog Mix 50
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2
Interventions: DRUG: Humalog Mix 50|DRUG: Human Insulin Mix 50:50
Outcome Measures: Primary: The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in IDDM patients treated BID with human insulin mix 50/50, vs the 2-hour PPBG excursion in patients treated BID with insulin lispro mix 50/50 | Secondary: The secondary objectives of the study are:|Assess hemoglobin A1c (HbA1c) values at baseline and after treatment with insulin lispro mix 50/50.|Assess HbA1c values at baseline and after treatment with human insulin mix 50/50.|To compare human insulin mix 50/50 with insulin lispro mix 50/50 with regard to|Effects on HbA1c values obtained at the end of each treatment period;|Effects on fasting blood glucose values obtained throughout the study;
Sponsor/Collaborators: Sponsor: Eli Lilly and Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 120
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2005-03
Completion Date: 2006-04
Results First Posted:
Last Update Posted: 2006-07-31
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Guangzhou, China
URL: https://clinicaltrials.gov/show/NCT00191581